SR-9011 5mg Capsules

Description

What Is SR-9011?

SR-9011 is a synthetic Rev-Erb alpha and beta agonist developed at the Scripps Research Institute by Professor Thomas Burris and colleagues. Rev-Erb nuclear receptors (NR1D1 and NR1D2) function as constitutive transcriptional repressors that play central roles in regulating circadian rhythm, lipid metabolism, inflammatory responses, and mitochondrial biogenesis. SR-9011 activates these receptors to modulate gene expression programs governing energy expenditure and metabolic homeostasis.

SR-9011 was developed as a successor to the closely related compound SR-9009 (stenabolic), with modifications intended to improve oral bioavailability, a known limitation of the earlier compound. Both compounds target the same Rev-Erb receptors, but SR-9011’s structural modifications address the pharmacokinetic challenges that limited SR-9009’s utility in oral research protocols. Preclinical studies demonstrated that SR-9011 increases oxygen consumption, reduces fat mass, enhances endurance capacity, and modulates circadian gene expression in rodent models, establishing it as a valuable tool in metabolic and chronobiology research.

Key Features and Specifications

Mechanism of Action: How SR-9011 Works

SR-9011 binds to and activates Rev-Erb alpha (NR1D1) and Rev-Erb beta (NR1D2), nuclear receptors that function as transcriptional repressors within the molecular clock machinery. Rev-Erb receptors regulate the expression of core clock genes including BMAL1 and CLOCK, as well as metabolic genes involved in lipogenesis, gluconeogenesis, and mitochondrial respiration. By enhancing Rev-Erb activity, SR-9011 shifts cellular metabolism toward increased energy expenditure and fatty acid oxidation.

In skeletal muscle, Rev-Erb activation by SR-9011 increases mitochondrial content and oxidative capacity, upregulating genes involved in the electron transport chain, citric acid cycle, and fatty acid beta-oxidation. These transcriptional changes produce measurable increases in oxygen consumption rate (OCR) and endurance performance in preclinical exercise models. In adipose tissue, SR-9011 represses lipogenic gene expression and reduces fat storage, contributing to overall fat mass reduction.

The compound’s effects on circadian rhythm regulation extend beyond metabolism. SR-9011 modulates inflammatory gene expression by repressing NF-kB target genes through Rev-Erb-dependent mechanisms, establishing anti-inflammatory activity in preclinical models of sepsis and autoimmune conditions. Importantly, SR-9011 does not interact with androgen receptors, estrogen receptors, or any hormonal pathway, making it a purely metabolic and circadian-modulating compound.

Reported Research Applications and Benefits

Metabolic research represents the primary application for SR-9011, with studies documenting increased resting metabolic rate, enhanced fatty acid oxidation, and reduced adipose tissue mass in treated animals. The compound’s ability to increase energy expenditure without requiring exercise stimulus has generated interest in obesity research, metabolic syndrome models, and exercise mimetic investigations.

Endurance and exercise physiology studies have demonstrated that SR-9011 enhances running capacity and time to exhaustion in rodent models, effects attributed to increased mitochondrial biogenesis and oxidative fiber recruitment in skeletal muscle. These findings parallel those observed with GW-501516, though SR-9011 operates through an entirely different receptor system.

Circadian biology research utilizes SR-9011 as a pharmacological tool to investigate Rev-Erb function in circadian gene regulation, sleep-wake cycle modulation, and the metabolic consequences of circadian disruption. Anti-inflammatory research has explored the compound’s ability to suppress pro-inflammatory cytokine production through Rev-Erb-mediated NF-kB repression in macrophages and other immune cells.

SR-9011 Dosage Information for Research

SR-9011 has a relatively short plasma half-life, and research protocols frequently employ split dosing to maintain more consistent Rev-Erb activation throughout the day. Because the compound is non-hormonal, it does not require post-cycle therapy and can be incorporated into combination research protocols alongside hormonal compounds without contributing additional suppression.

SR-9011 vs SR-9009: Key Differences

Storage and Handling Instructions

Store SR-9011 capsules at controlled room temperature between 20°C and 25°C (68°F to 77°F) in the original sealed container. Protect from direct sunlight, excessive heat, and moisture. Under recommended conditions, SR-9011 capsules maintain full potency for at least 24 months from the date of manufacture.

Why Choose PrymaLab SR-9011 Capsules

Every batch of PrymaLab SR-9011 undergoes independent third-party testing by accredited laboratories using HPLC for purity and mass spectrometry for identity confirmation. Each order includes a batch-specific Certificate of Analysis documenting ≥99% purity and comprehensive contaminant screening. Pharmaceutical-grade encapsulation ensures precise 5 mg dosing, and free priority shipping is included on all domestic orders.

Frequently Asked Questions About SR-9011

Is SR-9011 a SARM?

No. SR-9011 is a Rev-Erb nuclear receptor agonist, not a selective androgen receptor modulator. It does not bind to androgen receptors, does not influence testosterone or any hormonal pathway, and does not require post-cycle therapy. Its classification alongside SARMs in the market is a commercial convention rather than a pharmacological one.

How does SR-9011 improve over SR-9009?

SR-9011 was designed with structural modifications to address SR-9009’s notably poor oral bioavailability (approximately 2% in mice). While both compounds activate Rev-Erb alpha and beta receptors through the same mechanism, SR-9011’s enhanced metabolic stability and improved oral absorption make it more suitable for capsule-based research protocols.

Does SR-9011 affect hormones or require PCT?

No. SR-9011 operates entirely through the Rev-Erb nuclear receptor pathway, which is independent of androgen, estrogen, and all other hormonal signaling systems. It does not suppress testosterone, LH, or FSH, and post-cycle therapy is not required regardless of dose or duration.

Can SR-9011 be stacked with SARMs?

SR-9011 is frequently combined with SARMs and other compounds in research protocols because its non-hormonal mechanism adds metabolic and endurance-enhancing effects without contributing to hormonal suppression. Common research combinations include SR-9011 with GW-501516 for metabolic studies or SR-9011 with anabolic SARMs for body composition investigations.

What time of day should SR-9011 be administered in research?

Given SR-9011’s role in circadian gene regulation, timing of administration can influence experimental outcomes. Morning dosing aligns with the natural peak of Rev-Erb activity in diurnal organisms. For studies investigating circadian disruption or shift-work models, alternative timing protocols may be employed based on specific research objectives.

Quality Assurance and Testing

PrymaLab maintains pharmaceutical research-grade standards for all SR-9011 products. Each batch undergoes independent HPLC purity analysis, mass spectrometry identity confirmation, heavy metal screening, residual solvent testing, and microbial assessment by accredited third-party laboratories. Batch-specific Certificates of Analysis are provided with every order.

Research Disclaimer

SR-9011 is sold strictly for laboratory research and scientific investigation purposes only. This product is not intended for human consumption, veterinary use, or therapeutic application. SR-9011 has not been approved by the FDA or any regulatory agency for medical use. Purchasers must be qualified researchers affiliated with accredited institutions or licensed research organizations. By purchasing this product, you confirm that it will be used exclusively in accordance with all applicable local, state, and federal regulations governing research materials.